Cellular Therapy
Apheresis collection is our specialty and, building on over 30 years of experience, we have optimized cell collection by controlling and qualifying our apheresis procedures and collection sites, bringing a higher degree of reproducibility to research projects or manufacturing efforts based on cGMP and cGTP principles. Our extensive global portfolio of support services span non-clinical studies, clinical trials, and commercial product manufacturing, providing complementary resources and expertise to enhance your studies.
We apply our apheresis expertise towards the development and qualification of novel cell and gene therapies, assays, and medical devices. In addition, our program supports preclinical through Phase III trials and commercial operations, collecting cells from patients for cGMP manufacturing of clinical cell therapy products. We specialize in collecting primary hematopoietic and immune cells from peripheral blood with high-yield cell counts and cell viability including:
- Patient and normal-subject peripheral blood mononuclear cells (PBMCs)
- Mobilized peripheral blood progenitor cells (HPCs)
- Plateletpheresis products
To reduce variability and help you achieve your production goals and quality requirements, we operate using a comprehensive Quality Program, including:
- Controlled procedures and documentation
- Staff qualification and training
- Equipment management
- Corrective Action Preventive Action (CAPA)
HemaCare provides
Gold standard
- Predictable, reliable, and validated collection procedures
- Optimized Standard Operating Procedures
- Ability to collect based on specific protocol
- High-yield cell collections
- Validated, automated cell counts and five-part WBC differentials
Hassle-free ordering and delivery
- Rapid response time
- Ability to collect and provide on short notice
- Same day or overnight delivery
Much more...
- IRB approved collection protocols and subject consents
- Large registry of repeat-donor subjects
